DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rabavert (Rabies Vaccine Flury LEP) - Summary



RabAvert® Rabies Vaccine produced by Chiron Behring GmbH & Co KG is a sterile freeze-dried vaccine obtained by growing the fixed-virus strain Flury LEP in primary cultures of chicken fibroblasts.

RabAvert® is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups.

See all Rabavert indications & dosage >>


Published Studies Related to Rabavert (Rabies Vaccine Flury LEP)

Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. [2007.05.22]
On October 20, 1997, the U.S. Food and Drug Administration (FDA) licensed Purified Chick Embryo Cell (PCEC, RabAvert) vaccine against rabies in humans following clinical trials demonstrating safety and efficacy...

more studies >>

Clinical Trials Related to Rabavert (Rabies Vaccine Flury LEP)

Study of Intradermal Administration of PCEC Rabies Vaccine [Not yet recruiting]

Phase 2 FMP2.1 Trial in Mali [Active, not recruiting]
Malaria is a disease that affects many people in Africa. Malaria is caused by germs that are spread by mosquito bites. The purpose of this study is to compare the number of children who get malaria after receiving an experimental malaria vaccine (FMP2. 1/AS02A) to the number of children who get malaria after receiving a vaccine for rabies (an approved vaccine that does not prevent malaria). The children will be assigned to one of the vaccine groups by chance. Participants and doctors will not know which vaccine was given. Study participants will include 400 children, ages 1-6 years, living in Bandiagara, Mali. Children will receive 3 vaccine doses, by injection, to their upper arm. Study procedures will include physical exams and several blood samples. Participants will be involved in the study for 26 months.

Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children [Completed]
To assess the safety and reactogenicity of the FMP-1/AS02A malaria vaccine in malaria-exposed children living in western Kenya and aged 12-47 months

more trials >>

Page last updated: 2008-01-02

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015